Shareholder Services

Show All
Where is Strongbridge Biopharma incorporated?
Strongbridge Biopharma is an Irish public limited company.
Where are Strongbridge Biopharma’s U.S. headquarters?
The U.S. operations are based in Trevose, Pennsylvania, USA.
When was Strongbridge Biopharma founded?
Strongbridge Biopharma was established in 1996.
When did Strongbridge Biopharma go public in the U.S.?
Strongbridge Biopharma priced its initial public offering on NASDAQ Global Market on October 16, 2015 and trades under the ticker symbol SBBP.
What is Strongbridge Biopharma’s CUSIP number?
Strongbridge Biopharma’s CUSIP number is G85347 105.
Who is Strongbridge Biopharma’s transfer agent?
Communication regarding transfer requirements, lost certificates, changes of address, etc., should be directed to: Computershare

Written Inquiries:

Computershare
PO Box 43001
Providence RI 02940-30001

Or by overnight delivery:
Computershare
250 Royall St.
Canton, MA 02021

Email Inquiries:
web.queries@computershare.com

Telephone Inquiries:
Toll-Free: 866-490-6058 (US, Canada, Puerto Rico)
781-575-2784 (non-US)

Online Inquiries:
https://www-us.computershare.com/investor/Contact
When is Strongbridge Biopharma’s fiscal year end?
Strongbridge Biopharma’s fiscal year end is December 31.
How can I obtain Strongbridge Biopharma’s investor relations materials?
You may sign up to receive Strongbridge Biopharma’s press releases and SEC filings at the following link: Email Alerts.
How can I view the documents that Strongbridge Biopharma has filed with the U.S. Securities and Exchange Commission?
Strongbridge Biopharma’s U.S. Securities and Exchange Commission filings can be viewed on the SEC page.
Do you have another question that has not been answered?
For investor relations inquiries, you may submit inquiries via investors@strongbridgebio.com, or by contacting Mike Biega at The Trout Group, LLC. at +1-617-221-9660 or mbiega@soleburytrout.com.

For corporate or media relations inquiries, you may submit inquiries via media@strongbridgebio.com, or by contacting Lindsay Rocco at Elixir Health Public Relations at +1-862-596-1304 or lrocco@elixirhealthpr.com.